Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology
JF Gomes Marin, RF Nunes, AM Coutinho… - Radiographics, 2020 - pubs.rsna.org
Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning
M Cremonesi, ME Ferrari, L Bodei, C Chiesa… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) with 90 Y-labelled and 177 Lu-
labelled peptides is an effective strategy for the treatment of metastatic/nonresectable …
labelled peptides is an effective strategy for the treatment of metastatic/nonresectable …
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
JJ Zaknun, L Bodei, J Mueller-Brand, ME Pavel… - European journal of …, 2013 - Springer
Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …
involving the systemic administration of a radiolabelled peptide designed to target with high …
ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin …
The purpose of these guidelines is to assist physicians caring for patients with
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
L Bodei, M Kidd, G Paganelli, CM Grana… - European journal of …, 2015 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) with 90 Y and 177 Lu provides
objective responses in neuroendocrine tumours, and is well tolerated with moderate toxicity …
objective responses in neuroendocrine tumours, and is well tolerated with moderate toxicity …
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and …
U Garske-Román, M Sandström, K Fröss Baron… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
L Bodei, M Cremonesi, CM Grana, N Fazio… - European journal of …, 2011 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) is used in tumours expressing type 2
somatostatin receptors (sst 2), mainly neuroendocrine. The aim of this prospective phase I-II …
somatostatin receptors (sst 2), mainly neuroendocrine. The aim of this prospective phase I-II …
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
M Del Prete, FA Buteau, F Arsenault, N Saighi… - European journal of …, 2019 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed
injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses …
injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses …
Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions
S Okamoto, A Thieme, J Allmann… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy is increasingly
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …
Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment
M Sandström, U Garske-Román… - Journal of Nuclear …, 2013 - Soc Nuclear Med
The organs at risk in radionuclide therapy with 177Lu-octreotate are the bone marrow and
the kidneys. The primary aim of this study was to develop an individualized dosimetry …
the kidneys. The primary aim of this study was to develop an individualized dosimetry …